Floatz logo

Nivolumab

Lung Carcinoma

M.D. Anderson Cancer Centermonoclonal_antibodyPhase 2Active
B
63/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
48/ 100
Competitive Position
89/ 100

Competitive context

67 Active assets in the Lung Carcinoma cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
Taiho Oncology, Inc.
Phase 3BB
OTL-38
On Target Laboratories, LLC
Phase 4BB
ETOPOSIDE
SystImmune Inc.
Phase 3BB
Carboplatin
SystImmune Inc.
Phase 3B
Pembrolizumab
Essen Biotech
Phase 2B

View all 50 →

Same molecule, other indications

Nivolumab is also rated in:

Recurrent Non-Hodgkin LymphomaDormant
BBB
Indicative ·
74 / 100
View asset →
renal carcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
metastatic melanomaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →